Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

September 30, 2027

Conditions

Advanced Solid TumorsHematologic Malignancies

Interventions

DRUG

Pralatrexate Injection

Pralatrexate will be administered based on Child-Pugh Classification of liver impairment

Trial Locations (2)

RECRUITING

Gabrail Cancer Center, Canton

RECRUITING

TOI Clinical Research, Cerritos